The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...